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Adjunctive therapyBackground:Adenosine administered as an adjunct to reperfusion can reduce coronary no-reﬂowand limitmyocar-
dial infarct (MI) size in ST-segment elevationmyocardial infarction (STEMI) patients.Whether adjunctive adenosine
therapy can improve clinical outcomes in reperfused STEMI patients is not clear and is investigated in this meta-
analysis of 13 randomized controlled trials (RCTs).
Methods:We performed an up-to-date search for all RCTs investigating adenosine as an adjunct to reperfusion in
STEMI patients. We calculated pooled relative risks using a ﬁxed-effect meta-analysis assessing the impact of
adjunctive adenosine therapy on major clinical endpoint including all-cause mortality, non-fatal myocardial
infarction, and heart failure. Surrogate markers of reperfusion were also analyzed.
Results: 13 RCTs (4273 STEMI patients) were identiﬁed and divided into 2 subgroups: intracoronary adenosine ver-
sus control (8 RCTs) and intravenous adenosine versus control (5 RCTs). In patients administered intracoronary
adenosine, the incidence of heart failure was signiﬁcantly lower (risk ratio [RR] 0.44 [95% CI 0.25–0.78], P =
0.005) and the incidence of coronary no-reﬂow was reduced (RR for TIMI ﬂowb3 postreperfusion 0.68 [95% CI
0.47–0.99], P = 0.04). There was no difference in heart failure incidence in the intravenous adenosine group but
most RCTs in this subgroup were from the thrombolysis era. There was no difference in non-fatal MI or all-cause
mortality in both subgroups.
Conclusion:We ﬁnd evidence of improved clinical outcome in terms of less heart failure in STEMI patients adminis-
tered intracoronary adenosine as an adjunct to reperfusion. This ﬁnding will need to be conﬁrmed in a large
adequately powered prospective RCT.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Despite reperfusion by primary percutaneous coronary intervention
(PPCI), the morbidity and mortality of ST-segment elevation myocardial
infarction (STEMI) patients remain signiﬁcant. This may be, in part, due
to the presence of “myocardial reperfusion injury,” the term given to
the tissue injury and cardiomyocyte death, which occurs on reperfusing
previously ischemic myocardium and which contributes up to 50% ofscular Institute, Institute of
Hospitals Biomedical Research
ool, 67 Chenies Mews, London,
).
land Ltd. This is an open access articlthe ﬁnal myocardial infarct (MI) size [1,2]. Crucially, there is currently
no effective therapy for preventing myocardial reperfusion injury, and
as such novel therapies are required to target myocardial reperfusion
injury so as to reduce MI size and preserve left ventricular systolic func-
tion thereby preventing the onset of heart failure.
Experimental studies have established that administering adenosine
prior to index ischemia can reduce MI size in animal models of acute is-
chemia/reperfusion injury [3], but whether adenosine can also reduce
MI size when administered at the time of reperfusion has been less
clear [4,5]. Although treatmentwith adenosine as an adjunct to reperfu-
sion has been shown to prevent coronary no-reﬂow in STEMI patients,
whether it can also limit MI size and improve clinical outcomes in this
setting has been inconclusive [6–18]. Previous meta-analyses [19–21]
have failed to ﬁnd any beneﬁt of adjunctive therapy with adenosinee under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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did not include several recently published randomized control trials
(RCT) [22,16–18], including two studies reporting long-term clinical
outcomes [23,24]. Therefore, the aim of the current study was to per-
form an up-to-date meta-analysis of RCTs to determine whether aden-
osine administered as an adjunct to reperfusion improves clinical
outcomes in STEMI patients.
2. Methods
This study was performed according to the recommendations speciﬁed in the
Cochrane Handbook for Systematic Reviews of Interventions [25].
2.1. Eligibility criteria
All RCTs investigating the effect of adenosine (either intravenous or intracoronary) as
an adjunct to reperfusion on clinical endpoints in STEMI patients were eligible for inclu-
sion in the meta-analysis. RCTs comparing 3 arms were also included, provided we were
able to assess data for the adenosine and control groups.
2.2. Search strategy
We searched MEDLINE and EMBASE databases up to November 2014. Additionally,
we screened editorials and web-based sources of information to gain access to potential
data from newly available or retrieved studies. The following search terms were used:
“adenosine,” “adjunct,” “reperfusion injury,” “acute myocardial infarction,” “primary per-
cutaneous intervention,” “randomized.” Attempt was made to contact authors of
published RCTs when clinical endpoints were not reported.
2.3. Study selection
Two authors (HB, AS) identiﬁed suitable articles independently. Disagreement was
resolved through consensus from a third investigator (DJH). Fig. 1 shows the process of
study selection as per preferred reporting items for systematic reviews and meta-
analyses (PRISMA) [26].Fig. 1. PRISMA 20092.4. Data extraction and quality assessment
Baseline clinical characteristics of the study population, method of drug adminis-
tration, and clinical outcome measures were extracted. Trial quality was determined
as recommended by the Cochrane Handbook [25] (see Appendix A) but without con-
structing a composite quality score given the limitations inherent to such an approach
[27]. We aimed to produce a funnel plot if there were N10 included studies in the forest
plots.
2.5. Endpoints and deﬁnitions
The main clinical endpoints analyzed were all-cause mortality, non-fatal myocardial
infarction, and heart failure (deﬁned as both heart failure during the initial hospitalization
or rehospitalization for heart failure). Surrogate markers of reperfusion included ST-
segment resolution, TIMI coronary ﬂow b3 postreperfusion, myocardial blush grade 0 or
1, and side effects of adenosine (second and third degree atrioventricular block and hypo-
tension) were also analyzed.
2.6. Data synthesis and analysis
The RCTs were analyzed in 2 subgroups: intracoronary (IC) adenosine and intrave-
nous (IV) adenosine. RevMan 5.2 (Nordic Cochrane Centre) was used to conduct a
ﬁxed-effect meta-analysis for the pooled risk ratio (RR), with 95% conﬁdence intervals
for dichotomous outcomes. We combined the different dose arms of adenosine in the
pooled analysis against control. All reported P values are two-sided, with signiﬁcance
set at P b 0.05. Heterogeneity among trials was quantiﬁed using I2 statistics with I2 of
0–25%, 25–50% and 50–75% considered as low, moderate, and high heterogeneity,
respectively.
2.7. Sensitivity analyses
If adenosine therapy showed a beneﬁcial effect on a particular clinical endpoint, at-
tempts were made to test the robustness of the result by removing one study at a time
and looking at various subgroup analyses (trials using PPCI only; trials using thrombolysis
only; trials performed after 2005 to account for changes and improvement in PPCI; ex-
cluding trials including patients presenting within 6 hours of symptoms onset only; ex-
cluding trials reporting outcomes during or after hospitalization only).ﬂow diagram.
Table 1
Study characteristics.
Study and
year
Clinical setting
Country
N Adenosine dose Follow-up Outcomes
Intracoronary adenosine
Garcia-Dorado
2014
STEMI undergoing PPCI
Spain
201 IC 4.5 mg over 2 minutes distal
to the lesion immediately
before thrombectomy and
direct stenting
6 months Primary outcome: infarct size measured as total myocardial necrotic mass as
determined by late enhancement on CMR imaging performed between 2
and 7 days postreperfusion.
Secondary outcomes: differences between groups in ejection fraction and
ventricular volumes on the baseline CMR, in ejection fraction, infarct size,
and ventricular volumes on the CMR performed at 6 months, and the
difference between groups in creatine-kinase MB peak at the index episode.
MACE at 1 year⁎.
Niccoli 2013/
Oct 2013
STEMI undergoing PPCI
Italy
160 IC 120 μg as a fast bolus
followed by 2 mg over 2
minutes following thrombus
aspiration
1 year Primary endpoint: the incidence of ST-segment resolution N70% on surface
ECG at 90 minutes after PCI
Secondary endpoints: angiographic MVO incidence and MACE rate at 1 year
Grygier 2011/
2013
STEMI undergoing PPCI
Poland
70 IC 2 mg LCA, 1mg RCA,
immediately after crossing the
lesion and after ﬁrst balloon
inﬂation
1 year Primary endpoints: (1) ST-segment elevation resolution 60 minutes after
PCI, (2) MBG at the end of procedure, and (3) ﬁnal TIMI ﬂow grade and TIMI
frame count at the end of procedure
Secondary endpoints: (1) the composite endpoint of death, recurrent MI,
heart failure and clinically driven TVR during 1-month follow-up, and
(2) the composite endpoint of death, recurrent MI, heart failure, unplanned
hospitalization for heart failure and clinically driven TVR at 1 year
Desmet 2011 STEMI undergoing PPCI
Belgium
110 IC 4 mg bolus 1 year Primary endpoint: myocardial salvage, deﬁned as the percentage of the AAR,
which was not necrotic on MRI on Days 2–3
Secondary endpoint: MVO at Days 2–3, expressed as a percentage of the
AAR. Other secondary endpoints were TIMI ﬂow grade, TIMI frame count
and myocardial blush grade at the end of PCI, ST-segment resolution on the
ECG after PCI, MACE in hospital and at 30 days and at 1 year, recovery of LV
function as assessed using MRI at 4 months, evolution of cardiac markers in
the ﬁrst 24 hours
Fokkema 2009 STEMI undergoing PPCI
Netherlands
448 IC 2 × 120 μg after thrombus
aspiration and after stenting
1 month Primary endpoint: the incidence of residual ST-segment deviation b 0.2 mV,
30–60 minutes after PCI
Secondary endpoint: ST-segment elevation resolution, myocardial blush
grade, TIMI ﬂow on the angiogram after PCI, enzymatic infarct size, and
clinical outcome at 30 days
Stoel 2008 STEMI undergoing PPCI
Netherlands
49 IC 60 mg in 5–10 minutes after
last balloon inﬂation
1 year ST-segment resolution and ameliorates angiographic parameters of
coronary reﬂow (TIMI frame count, MBG, coronary blood ﬂow, coronary
vascular resistance). Follow-up for 12 months for clinical outcome
Petronio 2005 STEMI undergoing PPCI
Italy
60 IC 4 mg before ﬁrst balloon
inﬂation
6 months Primary endpoint was the prevalence of 6-month LV remodeling
Secondary endpoints were the following:(1) the prevalence of angiographic
no-reﬂow; (2) the ﬁnal corrected TIMI frame count, (3) the percentage
change in LVEDV at the 6-month follow-up
Marzilli 2000 STEMI undergoing PPCI
Italy
54 IC 4 mg in 1 minute after
balloon inﬂation
During
hospitalization
Primary endpoints: feasibility and safety of intracoronary adenosine
administration in the setting of primary PTCA and its effect on coronary
blood ﬂow
Secondary endpoints, indexes of myocardial damage, including LV regional
function, Q-wave MI, recurrence of angina, non-fatal MI, heart failure, and
cardiac death were evaluated during hospitalization
Intravenous adenosine
Zhang 2012 STEMI undergoing PPCI
China
90 IV 50 and 70 μg/kg/min after
the guide wire crossed the
lesion for 3 hours
6 months Primary endpoint: left ventricular function, and infarct size
Secondary endpoint: occurrence of cardiac and non-cardiac death, non-fatal
myocardial infarction, and heart failure at 6 months
Wang 2012 STEMI undergoing PPCI
China
69 IV 50 μg/kg/min for 3 hours,
started prior to stent
implantation
1 month To investigate the effect of intravenous adenosine on myocardial perfusion
and segmental contractile function when administered as an adjunct to PPCI
Clinical outcomeswere evaluated in terms of the occurrence ofMACE at 1month
Ross 2005 STEMI undergoing
PPCI/ thrombolysis
13 countries
2118 IV 50 and 70 μg/kg/min for 3
hours to be started within 15
minutes either of the start of
ﬁbrinolysis or before coronary
intervention
6 months Primary endpoint: new CHF beginning N24 hours after randomization, or
the ﬁrst rehospitalization for CHF, or death from any cause within 6 months.
Infarct size was measured in a subset of 243 patients by SPECT
Secondary endpoints: all-cause and cardiovascular mortality within 6
months and those speciﬁc to the infarct size sub-study
Quintana 2003 STEMI undergoing
thrombolysis
Sweden
608 IV 10 μg/kg/min started with
thrombolysis and maintained
for 6 hours
12 months Primary endpoint; global and regional left ventricular systolic and diastolic
function by echocardiography
Secondary endpoint: all-cause and cardiovascular mortality, and non-fatal
myocardial infarction during 12 months of follow-up
Mahaffey 1999 STEMI undergoing
thrombolysis
USA/ Canada/
Argentina
236 IV max 70 μg/kg/min for 3
hours before thrombolysis
together with lignocaine
4–6 weeks Primary endpoint: infarct size as determined by SPECT imaging at 6 ± 1 days
Secondary endpoints: MSI and a composite of in-hospital clinical outcomes
(death, re-infarction, shock, congestive heart failure, or stroke)
Abbreviations: STEMI: ST-elevation myocardial infarction; PPCI: percutaneous coronary intervention; IV: intravenous; IC: intracoronary; MVO: microvascular obstruction; LV left
ventricle; LVEF: left ventricular ejection fraction; MRI: magnetic resonance imaging; TIMI: thrombolysis in myocardial infarction; MACE: major adverse cardiovascular event; MBG:
myocardial blush grade; TVR: target vessel revascularisation; LVEDV: left ventricular end diastolic volume; PTCA: primary transcutaneous coronary angioplasty
⁎ Unpublished follow-up data obtained from Garcia-Dorado 2014
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3.1. Description of included studies
A total of 210 articles were retrieved from the search and 16 RCTs
satisﬁed the predetermined inclusion criteria study review (Fig. 1). Of
these, only 12 RCTs had investigated the effect of adenosine on clinical
outcomes in STEMI patients. Furthermore, 1-year outcome data were
obtained for the authors of the recently published PROMISE trial [22],
which originally investigated the effect of intracoronary adenosine on
infarct size by cardiacmagnetic resonance. Two RCTs have subsequently
reported clinical outcomes at 1 year [24,23], and these were used for
data extraction. Therefore, 8 RCTs using IC adenosine and 5 RCTs using
IV adenosine were included in the meta-analysis. Table 1 shows the
baseline characteristics of the 13 included RCTs. The study characteris-
tics and the baseline demographics and inclusion and exclusion criteria
are detailed in Table 1 and Appendices B and C.
Ji (2007) [28], Wang (2008) [29], and Akturk (2014) [30] were 3
very small trials with no clinical endpoints reported andwere therefore
not included in this analysis.
3.2. Quality assessment
The quality of the RCTs is shown in Appendix A. Randomization was
assessed and considered adequate for 4 out of 13 trials. Although 8 of
the studies were open-label, blinded observers independently adjudi-
cated the endpoints in all of them.We did not formally test for publica-
tion bias, but we did attempt to directly contact investigators for clinical
outcome data, which partly reduced the risk of publication bias.
3.3. Major clinical endpoints
The clinical endpoints are detailed in Table 2. All-cause mortality
data were available for 7 out of 8 IC adenosine trials and for 4 out of 5
IV adenosine trials. Data on non-fatal MI were available for 4 out of 8
IC adenosine trials and for 3 out of 5 IV adenosine trials. There was no
statistically difference in the incidence of non-fatal MI or all-cause
mortality between adenosine and control for both routes of adenosine
administration as shown in the Forest plots in Figs. 2 and 3. The deﬁni-
tions for heart failure endpoints in each trial are listed in Table 3. Heart
failure outcomeswere available for 5 out of the 8 IC adenosine trials and
for all of the IV adenosine trials as shown in Fig. 4. Therewas a reduction
in heart failure outcomes in the IC adenosine subgroup (RR 0.44, 95% CI
0.25–0.78, P = 0.005) but no difference in the IV adenosine subgroup
(RR 1.04, 95% CI 0.81–1.33, P = 0.36).Table 2
Clinical endpoints.
Study Major adverse
cardiovascular event
Target vessel/ lesion
revascularisation/ stent
thrombosis
Adenosine Control Adenosine Control
Garcia-Dorado 2014 NA NA 3⁎ 9⁎
Niccoli 2013/ Oct 2013 10 23 6 7
Grygier 2011/ 2013 8 16 3 3
Desmet 2011 NA NA NA NA
Fokkema 2009 14 10 8 7
Stoel 2008 6 5 1 0
Petronio 2005 NA NA NA NA
Marzilli 2000 5 13 NA NA
Zhang 2012 19 11 NA NA
Wang 2012 3 5 NA NA
Ross 2005 231 126 NA NA
Quintana 2003 61 64 NA NA
Mahaffey 1999 22 16 NA NA
⁎ Unpublished follow-up data obtained from Garcia-Dorado 20143.4. Surrogate markers of reperfusion and safety endpoints
The details of the surrogate markers of reperfusion and safety end-
points for each trial are listed in Appendix D. Data on ST-segment reso-
lution were available for 7 out of 8 IC adenosine trials only. However, as
therewas signiﬁcant heterogeneity in the studies (Chi2= 16.42, df= 6,
P = 0.01; I2 = 63%), no summary effect size was estimated. Thrombol-
ysis in myocardial infarction (TIMI) ﬂow b3 postprocedure was avail-
able in 7 out of 8 IC adenosine trials. TIMI ﬂow b3 postprocedure
occurred with reduced incidence in the IC adenosine arm compared to
control (RR 0.68 [95% CI 0.47–0.99], P = 0.04) (Fig. 5). Myocardial
blush grade (MBG) of 0 or 1 was documented in 5 out of 8 IC adenosine
RCTs. There was a trend toward less occurrence of MBG 0 or 1 in the
adenosine group but this did not reach statistical signiﬁcance (RR 0.87
[95% CI 0.70–1.08], P = 0.22) (Fig. 6). Examining these 5 studies in
more detail, 400 μg of IC nitroglycerin was used in Fokkema et al. [13]
in both arms prior to adenosine. Excluding this study from the analysis
showed a lower incidence of MBG 0 or 1 in the adenosine group (RR
0.69, 95% CI 0.49–0.97, P = 0.03). As expected, both IV adenosine and
IC adenosine were more likely to cause second and third degree heart
block (IV adenosine: RR 2.86 [95% CI 1.63–5.02], P b 0.001; IC adenosine:
RR 6.24, [95% CI 3.21–12.14], P b 0.001) and hypotension (IV adenosine:
RR 1.19 [95% CI 1.03–1.38], P = 0.02; IC adenosine: not estimable) but
these effects were transient in nature and none of the trials reported
any long-lasting sequelae.
3.5. Sensitivity analyses
The reduction in the incidence of heart failurewas still present in the
IC adenosine subgroup despite removing one trial at a time; including
trials using PPCI only (6 IC RCTs and 2 IV RCTs) and after only including
trials published after 2005. This beneﬁt persisted when only trials
reporting outcomes after 6–12months follow-up (5 IC RCTs) were con-
sidered. When trials including patients with up to 12 hours of symp-
toms duration were considered (6 RCTs), this beneﬁt in heart failure
reduction was no longer present but there was a trend toward less
heart failure when IC adenosine trials (3 RCTs) only were considered
(Appendix E).
4. Discussion
We show for the ﬁrst time, improved clinical outcomes in STEMI
patients administered adenosine as an adjunct to reperfusion. Our
meta-analysis found that IC adenosine given at the time of PPCI reduced
the incidence of heart failure in STEMI patients. This ﬁnding was as-
sociated with improved myocardial reperfusion as evidenced by aDeaths Non-fatal myocardial
infarction
Heart failure
Adenosine Control Adenosine Control Adenosine Control
4⁎ 2⁎ 0⁎ 0⁎ 3⁎ 6⁎
2 4 1 5 1 7
0 0 2 3 6 11
2 2 NA NA NA NA
3 2 3 1 NA NA
2 1 NA NA 3 4
2 1 NA NA NA NA
0 5 0 1 2 5
3 4 4 2 14 6
0 0 0 0 3 5
146 83 NA NA 116 58
32 39 35 38 14 14
10 6 7 3 13 8
Fig. 2. Forest plot for all-cause mortality, adenosine v control.
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postreperfusion TIMI ﬂow b3 and less occurrence of MBG 0 or 1 (after
excluding one study [13] using IC nitroglycerin in both arms prior to
adenosine which itself has been shown to improve the microvascular
dysfunction [31] and may have contributed to the neutral result in
MBG0 or 1with adenosine in that study). The beneﬁcial effects of aden-
osine were conﬁned to those STEMI patients in whom adenosine was
given via the IC route with no positive effects found with intravenously
administered adenosine. However 3 out of 5 RCTs [6,8,11] administer-
ing IV adenosine were also confounded by the fact that they were per-
formed in the thrombolysis era and therefore there is inadequate RCTs
in this subgroup to allow us to draw anymeaningful conclusion regard-
ing IV adenosine in the PPCI setting.Fig. 3. Forest plot for non-fataIn our meta-analysis, we found that IC adenosine therapy reduced
the incidence of heart failure (during index admission or rehospitaliza-
tion for heart failure), but there was no beneﬁt in other major clinical
endpoints of death, non-fatal MI, or revascularization. This beneﬁt was
still present despite excluding one RCT [7] in the intracoronary group
looking at heart failure during hospitalization only (hospitalization for
heart failure was available at 1 year for the remaining 4 RCTs [22–24,
12] – Table 3) and excluding the unpublished follow-up data from the
PROMISE trial [22]. The beneﬁcial effect of adenosine on heart failure
most likely relates to the impact of adenosine therapy of preventing
myocardial reperfusion injury and reducing MI size, although a favor-
able effect on ventricular remodeling cannot be ruled-out. Adenosine,
via various adenosine receptor agonists, has been shown to reducel MI, adenosine v control.
Table 3
Heart failure time points.
Study Heart failure
Garcia-Dorado 2013
abstract only
Hospitalization for heart failure at 1 year⁎
Niccoli 2013/ Oct 2013 Hospitalization for heart failure at 1 year
Grygier 2011/ 2013 Not clearly deﬁned. Heart failure at 1 year
Stoel 2008 Not clearly deﬁned. Heart failure at 1 year
Marzilli 2000 Heart failure during hospitalization
Zhang 2012 Heart failure during hospitalization
Wang 2012 Heart failure at 1 month
Ross 2005 Heart failure during hospitalization and
rehospitalization for heart failure during 6 months
Quintana 2003 Heart failure during hospitalization
Mahaffey 1999 Heart failure during hospitalization
⁎ Unpublished follow-up data obtained from Garcia-Dorado 2014.
233H. Bulluck et al. / International Journal of Cardiology 202 (2016) 228–237reperfusion injury and subsequent infarct size in animal models
through the activation of the reperfusion injury salvage kinase pathway
[32]. It is also known to be a potent vasodilator [33], to have anti-
inﬂammatory properties [34] and has been implicated in the blockade
of the neutrophil-mediated processes that promote microvascular ob-
struction [35]. Therefore, through these pleiotropic effects, adenosine
can reduce infarct size and microvascular obstruction (MVO) and re-
duce the risk of adverse LV remodeling and heart failure.
The main strength of our study over previously published meta-
analyses [19,21,20] is the inclusion of several recently published clinical
outcomes studies [24,23,18,22].
The REFLO-STEMI trial [36] (240 patients) looking at the effect of IC
adenosine, sodium nitroprusside, and standard therapy on infarct size
and MVO by cardiovascular MRI has completed recruitment and the
results from this study would add to the current evidence on the role
of IC adenosine in PPCI.
5. Limitations
There are several limitations to our meta-analysis. Firstly, the dura-
tion of symptoms varied among the RCTs, which may have diluted any
beneﬁcial effect observed with adenosine. Although we did attempt toFig. 4. Forest plot for heart faiexplore trials including patients presenting within 6 hours of symptom
onset, the majority of patients recruited within that time frame were
confounded by also being treated by thrombolysis. Secondly, the dose
of IV and IC adenosine differed greatly between studies (Table 1), and
so it is difﬁcult to ascertain the optimal IC dose of adenosine that had
themost beneﬁt. Thirdly, the timing of adenosine administration varied
between studies ranging from initiating the IV infusion prior to reperfu-
sion, and others administering the IC injection after the last balloon in-
ﬂation. Finally, the RCT Stoel 2008 [12] only included patients with
suboptimal ST-segment resolution and used a very high dose of IC aden-
osine. However, thiswas a small study and did notweigh signiﬁcantly in
the various analyses.6. Conclusion
In summary, ourmeta-analysis shows for the ﬁrst time that IC aden-
osine administered as an adjunct to reperfusion can improve clinical
outcome as evidenced by a reduction in the incidence of heart failure
in STEMI patients. The ﬁndings from this study are especially important
for STEMI patients given the fact that despite recent reductions in mor-
tality, the incidence of heart failure in this patient group is increasing.
We hope that the ﬁndings from our meta-analysis will add to the posi-
tive evidence supporting the beneﬁts of adenosine as an adjunct to re-
perfusion in STEMI patients and pave the way for large-scale
prospective RCTs to conﬁrm this beneﬁcial effect of adenosine on
major clinical outcomes.Disclosures
No conﬂict of interests ot relationship with industry exists.Funding
This work was supported by the British Heart Foundation (FS/10/
039/28270), the RoseTrees Trust, and the National Institute for Health
Research University College London Hospitals Biomedical Research
Centre.lure, adenosine v control.
Fig. 5. Forest plot for myocardial blush grade 0 or 1, adenosine v control.
Fig. 6. Forest plot for TIMI ﬂow b3, adenosine v control.
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N
G
D
Fo
St
P
M
Z
W
RRandomization sequence
generation (was the method
of generating the random
sequence stated?)Allocation concealment
(following randomization, was
allocation of intervention
satisfactorily concealed, e.g.
remote or centralized center,
sealed opaque envelopes?)Blinding of participants,
personnel, and outcome (what
type of blinding, and any speciﬁc
detail on who was blinded?)What percentage of
patients was lost to
follow-up?Missing outcome data (were
there any prespeciﬁed outcomes
in the methods section that the
authors said they would assess
and report, but we were unable
to extract the data for?)arcia-Dorado
2014The randomization sequence
was performed in permuted
block sizes of 5 and 5.NA Double blinded 17 patients NAiccoli 2013/
Oct 2013Through an envelope opened
by a traineeNA Open label
Blind examination2 patients NArygier 2011/
2013NA NA Blinded outcome adjudication NA NAesmet 2011 Computer-generated
randomizationList kept in a sealed envelope
hospital pharmacyDouble blinded NA Data on major adverse cardiac
events not presentedkkema 2009 NA NA Open label trial with blinded
evaluation of endpointsNA NAoel 2008 NA NA Double blinded 1 (+1 cross-over)
patientsNAetronio 2005 Randomization in a
sequential alternating fashionNA Blinded evaluation of endpoints NA NAarzilli 2000 NA NA Blinded evaluation of
angiogramsNA NAhang 2012 NA NA Blinded evaluation of cardiac
echo and perfusion imagingb20% NAang 2012 NA NA Blinded evaluation of clinical
and angiographic dataNA NAoss 2005 NA NA Double blinded NA NA
(A
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Study Randomization sequence
generation (was the method
of generating the random
sequence stated?)Allocation concealment
(following randomization, was
allocation of intervention
satisfactorily concealed, e.g.
remote or centralized center,
sealed opaque envelopes?)Blinding of participants,
personnel, and outcome (what
type of blinding, and any speciﬁc
detail on who was blinded?)What percentage of
patients was lost to
follow-up?Missing outcome data (were
there any prespeciﬁed outcomes
in the methods section that the
authors said they would assess
and report, but we were unable
to extract the data for?)uintana 2003 NA NA Double blinded 2 patients NA
ahaffey 1999 NA NA Blinded evaluation of imaging
studies
NA NAAppendix B. Baseline demographicsStudy Number of
patients in
adenosine groupNumber of
patients in
control groupFollow-up Age
(mean)Male
(%)Smoker
(%)Diabetes
mellitus (%)Prior
MI (%)LAD
infarct (%)Proximal
occlusion (%)Pre-PCI
TIMI 0/1 (%)arcia-Dorado 2014 100 97 6 months 59 86 52 15 NA NA NA 100
iccoli 2013/ Oct 2013 80 80 1 year 64 76 58 23 22 46 50 86 (TIMI 0)
rygier 2011/ 2013 35 35 1 year 65 62 50 23 10 19 NA All patients
TIMI 0-2 pre-PCI
esmet 2011 56 54 1 year 61 82 49 10 1 41 NA 72
kkema 2009 226 222 1 month 62 75 58 10 8 40 61
oel 2008 27 22 1 year 67 66 36 11 NA 51 NA NA
etronio 2005 30 30 6 months 58 85 52 20 NA 58 NA 100
arzilli 2000 27 27 During
hospitalization
60 80 NA NA 13 52 NA NAang 2012 59 31 6 months 63 81 59 33 NA 47 NA 96.3% of patients
TIMI 0-2 pre-PCIang 2012 35 34 1 month 57 83 46 19 0 65 NA NA
oss 2005 1415 703 6 months 60 73 NA 16 13 100 NA NA
uintana 2003 302 306 12 months 65 76 32 9 23 NA NA NA
ahaffey 1999 119 117 4–6 weeks 58 72 81 22 15 39 NA NAMAbbreviations: MI: myocardial infarction; LAD: left anterior descending artery; PCI: percutaneous coronary intervention; TIMI: thrombolysis in myocardial infarction.Appendix C. Inclusion and exclusion criteriaStudy Inclusion criteria Exclusion criteriaarcia-Dorado 2014 Over 18 years of age with a diagnosis of STEMI on ECG and receiving
PCI within 6 hours of symptom onset.Previous myocardial infarction and TIMI ﬂow grade 1 on initial angiography.
Patients with potential contraindications for adenosine and contraindications
for MRI examination or for gadolinium administration (renal function
b30 mL/min/1.73 m2) or those with life expectancy of less than 6 months.iccoli 2013/ Oct 2013 Symptom onset b12 hours before enrolment, ST-segment elevation
of at least 2 mm in 2 or more contiguous leads, and thrombolysis in
myocardial infarction (TIMI) ﬂow grade 0/1 at baseline angiography.Age b18 years, previous STEMI in the same territory of current admission, cardio-
genic shock, pregnancy, history of renal failure (serum creatinine N3 mg/dl),
contraindications to contrast agents or other study medications, paced rhythm,
frequent ventricular ectopy, left bundle branch block, pre-excitation or other
conditions or artifacts interfering with interpretation of the ST segment, culprit
lesion located in a bypass graft, stent thrombosis, unidentiﬁed culprit lesion, and
left main disease.rygier 2011/ 2013 6 hours of symptom onset, TIMI ﬂow 0–2 TIMI ﬂow 3, patients with chronic obstructive pulmonary disease or asthma
and those who had received previous thrombolysis were excluded..esmet 2011 Cardiac sounding chest pain of at least 20 minutes x, a time from
onset of symptoms of b12 hours, and an ECG showing ST-segment
elevation of .0.1 mV in two or more limb leads or .0.2 mV in two or
more contiguous precordial leads, or presumed new left bundle-
branch block.Contraindication to heparin, low-molecular-weight heparin or clopidogrel, an-
ticipated difﬁcult vascular access, cardiogenic shock, inability to give informed
consent, high-grade atrioventricular block, severe asthma, treatment with
theophylline, glibenclamide, or dipyridamole, prior coronary artery surgery,
and participation in any investigational drug or device study within the past
30 days.kkema 2009 Symptoms of chest pain suggestive for myocardial ischemia for at least
30 minutes, a time from onset of symptoms of b12 hours before
hospital admission, and an ECG showing ST-segment elevation
of N0.1 mV in 2 or more leads.The presence of cardiogenic shock, existence of a life-threatening disease with
a life expectancy of b6 months, receiving pharmacotherapy for chronic
obstructive pulmonary disease, or no informed consent.oel 2008 Following successful (deﬁned as TIMI ﬂow grade 2 or 3 without
residual dissections or stenosis N30% and no angiographic evidence
of embolisation) PCI for acute myocardial infarction, patients with
suboptimal reperfusion (b70% STRes with persistent ST-elevation
N2 mV in at least one anterior lead and N1 mV in a nonanterior lead)
more than 10 minutes after last balloon inﬂation could be included.Excluded were patients with hemodynamic instability, prior myocardial
infarction or an ECG unsuitable for calculation of STRes (left bundle branch
block, paced or severe disturbed rhythm). In addition, patients with a history of
obstructive pulmonary disease were excluded because of potential side effects
of adenosine.(continued on next page)
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Qtudy Inclusion criteria Exclusion criteriaetronio 2005 Presentation N 6 hours from symptom onset; chest pain lasting 30
minutes and resistant to nitrates; 0.2 mV ST-segment elevation in 2
contiguous leads on a 12-lead electrocardiogram; TIMI ﬂow 0–1 in the
infarct-related artery at the diagnostic angiogram; absence of contra-
indications to abciximab and adenosineSigniﬁcant left main coronary disease; cardiogenic shock; AMI due to bypass
graft occlusion; thrombolytic therapy before angioplastyWithdrawals or losses
to follow-up: not reportedarzilli 2000 Referred for PTCA within 3 hours from the onset of AMI; the culprit
lesion was suitable for PPCI; presented with a TIMI ﬂow from 0 to 2;
informed consentTIMI 3 ﬂow and having spontaneous reperfusion; a history of bronchospasm
and/or undergoing therapy with theophylline derivatives; had received
thrombolytics in the emergency roomhang 2012 (1) typical chest pain presenting within 12 hours of onset, with
ST-segment elevation in at least two contiguous leads of N0.2 mV in
precordial
leads, N0.1 mV in limb leads, or new left bundle branch block (LBBB),
(2) they were candidates for primary PCI treatment, (3) N18 years of
age.(1) thrombolytic treatment before PCI treatment, (2) previous myocardial
infarction, (3) a history of coronary artery bypass graft (CABG) or PCI, (4) cor-
onary angiography conﬁrmed multi-vessel disease, (5) hypotension with sys-
tolic blood pressure b90 mmHg or cardiogenic shock, or persistent bradycardia
with heart beat b55 beats/min, or advanced atrioventricular block without a
pacemaker, (6) clinical evidence of signiﬁcant reactive airway disease
(e.g., asthma), or (7) advanced cancer, or end-stage disease.ang 2012 Patient who had received primary PCI within 12 hours of the onset of
STEMI.A history of myocardial infarction or coronary artery bypass grafting; cardiogenic
shock; left ventricular ejection fraction b 40%; creatinine N3 mg/dL; a history or
clinical evidence of bronchospastic lung disease; second-degree or greater atrio-
ventricular block without a functional pacemaker; atrial ﬁbrillation; and allergy
to adenosine.oss 2005 Age over 18 years, reperfusion therapy (ﬁbrinolysis or percutaneous
intervention) within 6 hours of onset of ischemic type pain (≥30
minutes), and electrocardiographic evidence of anterior STEMI.
Electrocardiographic requirements were either ≥2 mm of
ST-segment elevation in at least two contiguous precordial leads or
(presumed) new left bundle branch block.Initiation of reperfusion therapy before initiation of study drug. MI precipitated by
a condition other than atherosclerotic CAD. Systolic blood pressure b90 mmHg
including cardiogenic shock and not responsive to intravenous ﬂuids. Sustained
bradycardia. Clinical evidence of signiﬁcant reactive airway disease. Greater than
ﬁrst-degree atrioventricular block without functional pacemaker. Received
dipyridamole within 24 hours of e. Coexistent condition associated with a limited
life expectancy. Participation in another clinical research study.uintana 2003 Patients b80 years of age with characteristic chest pain presenting
within
12 hours of onset, with ST-segment elevation N0.1 mV in at least two
contiguous leads and being candidates for thrombolytic treatment
were eligible for enrolment. Patients had to be on beta-blockers or
planning to receive beta-blockers to be eligible.Age b18 years, pregnancy or lactation, second-degree or greater
atrioventricular block without permanent pacemaker and current enrolment in
other clinical trials.ahaffey 1999 Patients presenting within 6 hours of the onset of chest pain
(consistent with ischemia, lasting at least 20 minutes, and not
relieved by sublingual nitroglycerin) who had ST-segment elevation
N0.1 mV in two contiguous leads, in whom the clinical decision was
made to treat with thrombolytic therapy, were eligible for
enrolment.b18 years or N79 years, women known or suspected to be pregnant, lactation,
dipyridamole treatment within the past 24 hours, systolic blood pressure b100
mmHg, cardiogenic shock, underlying condition in which hypotension may be
poorly tolerated, history or clinical evidence of bronchospastic lung disease or
prior bronchodilator therapy, second-degree or greater atrioventricular block
without functional pacemaker, LBBB, sustained bradycardia, current enrolment
in other investigational drug studies, and patients unlikely to be available for
follow-up.Abbreviations: STEMI: ST-elevation myocardial infarction; TIMI: thrombolysis in myocardial infarction; STRes: ST-segment resolutionAppendix D. Angiographic, electrographic, and adenosine related side effectsStudy Angiographic data ST-segment
resolution on ECGPostadenosinePostprocedural
TIMI ﬂow b3Angiographic no
reﬂow/ slow ﬂowMBG 0–1 Bradycardia 2nd degree/ 3rd
degree heart blockHypotensionAdenosine Placebo Adenosine Placebo Adenosine Placebo Adenosine Placebo Adenosine Placebo Adenosine Placebo Adenosine Placeboarcia-Dorado
20146 12 0 3 12 15 66 45 2 4 2 0 1 0iccoli 2013/
Oct 20137 8 NA NA 7 16 57 41 1 0 11 2 5 7rygier 2011/
20133 8 0 3 5 9 27 15 8 0 NA NA 0 0esmet 2011 11 7 NA NA 19 21 24 21 5 7 13 5 NA NA
kkema 2009 13 14 2 1 70 66 154 147 34 5 31 2 24 2
oel 2008 NA NA NA NA NA NA 9 2 NA NA NA NA NA NA
etronio 2005 2 4 4 5 NA NA 13 16 NA NA 5 0 NA NA
arzilli 2000 0 8 1 7 NA NA NA NA 0 0 0 0 0 0
hang 2012 1 4 3 11 2 9 NA NA 7 1 12 1 12 3
ang 2012 4 5 NA NA NA NA NA NA NA NA 0 0 NA NA
oss 2005 NA NA NA NA NA NA NA NA 38 16 56 7 263 98
uintana 2003 NA NA NA NA NA NA NA NA 79 86 3 5 79 86
ahaffey 1999 NA NA NA NA NA NA NA NA 19 12 5 3 44 36MAbbreviations: MBG: myocardial blush grade; TIMI: thrombolysis in myocardial infarction.
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6Studies Participants Effect estimate
Risk ratio (M–H, ﬁxed, 95% CI)PCI only 8 799 0.59 [0.39, 0.92]
rombolysis (IV adenosine before reperfusion) 3 2962 1.13 [0.79, 1.62]
ials after 2005 7 745 0.62 [0.39, 0.97]
uration of symptoms up to 12 hours 6 1086 0.80 [0.51, 1.25]
uration of symptoms up to 12 hours (IC group only) 3 319 0.38 [0.14, 1.04]
–12 months follow-up 8 3381 0.85 [0.67, 1.09]
–12 months follow-up (IC group only) 5 586 0.46 [0.25, 0.84]6References
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